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Background. The preferred treatment method of most hydatidiform moles is suction aspiration. In rare circumstances uterine
abnormalities may preclude surgical treatment. Case. We report a case of complete molar pregnancy successfully treated with
methotrexate followed by EMA/CO. A 38-year-old woman with a complete hydatidiform mole and multiple uterine ﬁbroids
underwent a failed attempt at suction aspiration. Following treatment with methotrexate, a nonmetastatic persistent trophoblastic
tumour developed. Six cycles of EMA/CO led to complete remission. Conclusion. We propose that primary treatment of molar
pregnancies with chemotherapy is a useful treatment option in cases where uterine abnormalities interfere with suction aspiration.
Copyright © 2009 M. De Vos et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
With an incidence of approximately 0.5 to 1 in 1000
pregnancies in Caucasians, hydatidiform mole (HM) is a
relatively rare disorder of trophoblast proliferation, with
broad variations in incidence worldwide [1]. HM is a pre-
neoplastic disorder, and there is a substantial risk that the
condition develops into a frankly malignant tumour. In that
respect, it is important to distinguish between a complete
hydatidiform mole (CHM), which is usually androgenetic
and displays merely vestigial embryonic development, and
a partial hydatidiform mole (PHM), which is typically
triploid and shows coexistence of an embryoand trophoblast
hyperplasia. A complete hydatidiform mole confers a greater
malignant potential: 15 to 20% of CHM will eventually
develop into a gestational trophoblastic tumour requiring
the administration of chemotherapy, as compared to only 2
to 4% of PHM [2]. Nevertheless, irrespective of whether a
hydatidiform mole is complete or partial, appropriate treat-
ment is of uttermost importance because of the neoplastic
potential. Suction curettage is regarded as the preferred
treatment method [3]. Hysterectomy can be oﬀered in
selected multiparous patients but will not cure the patient
if an extrauterine invasive component cannot be ruled out.
Medical methods of evacuation of uterine content, such as
misoprostol and antiprogesterone, are less eﬃcient [4, 5]. In
contrast with its use in low-risk nonmetastatic gestational
trophoblast neoplasia (GTN) following suction curettage,
therearenoreportsoftheuseofmethotrexateastheprimary
treatment of a hydatidiform mole located within the uterine
cavity. Here, we describe the management of a complete
hydatidiform mole using systemic methotrexate in a patient
in whom suction curettage was incomplete because of severe
distortion of the uterine cavity by ﬁbroids.
2. Case Presentation
A 38-year-old G1P0A1 was referred to the reproductive
medicine outpatient clinic because of a two-year history
of infertility. Her medical history was uneventful apart
from menorrhagia. A transvaginal ultrasound scan revealed
the existence of three intramyometrial ﬁbroids, measuring
between 30 and 40mm. Outpatient hysteroscopy showed
intrusion of the ﬁbroids into the endometrial cavity, so that
the distant half of the cavity was inaccessible for inspection
with a 5.5mm rigid hysteroscope. The patient was advized to
undergo a three-month course of gonadal suppression with
long-acting GnRH-agonists (triptorelin), in order to achieve
a size reduction of the ﬁbroids prior to assisted reproductive
treatment. However, she declined this advice. Two months
later the patient was spontaneously pregnant.2 Case Reports in Medicine
Atnine-weekgestationaroutineultrasoundscanshowed
gross enlargement of the uterine cavity, hydropic changes
compatible with a diagnosis of HM, and no intrauterine
gestational sac. The total serum hCG level was 4282IU/L.
Suction curettage was attempted under ultrasound guidance
but only yielded a very limited amount of conception
products as the largest part of molar tissue was localized in
the inaccessible distal part of the cavity. One day after the
procedure, the hCG level dropped to 3618IU/L. Histopatho-
logical analysis of the small tissue sample conﬁrmed the
diagnosis of a complete hydatidiform mole.
Since the patient declined the option of a hysterec-
tomy, interval chemotherapy with methotrexate was oﬀered.
Although there was no evidence of GTN at the start of
methotrexate treatment, we adapted the interval treatment
regimen for GTN, as advocated by the FIGO (FIGO
2000 management guidelines). Methotrexate 1mg/kg was
administered i.m. on days 1, 3, 5, and 7, and folinic acid
0.1mg/kg i.m. on alternate days. This regimen was repeated
after a treatment-free window of 10 days, in accordance
with literature guidelines [6]. After these two cycles of
methotrexate, serum hCG levels plateaued at between 10 and
40IU/l (a total of nine fortnightly measurements),consistent
with a diagnosis of GTN (Figure 2). GTN staging included
a CT-scan of the thorax and of the abdomen (Figures
1(a) and 1(b)), and did not demonstrate any extrauterine
metastases. Subsequently, six cycles of EMA/CO multiagent
chemotherapy, including etoposide 100mg/m2, methotrex-
ate 300mg/m2 a n da c t i n o m y c i nD0 . 5 m go nd a y1a n d2
and cyclophosphamide 600mg/m2, and vincristine 1mg/m2
(maximum dose of 2mg) on days 8, were administered
intravenously every 3 weeks. Because of paresthesia grade
3 in both feet, vincristine was omitted in the ﬁfth and the
sixth cycles. There was no evidence of hematological toxicity.
Serum hCG had reached normal levels after the sixth cycle of
EMA/CO.Completeremissionwasdiagnozedafterachieving
over twelve months of undetectable serum hCG levels and a
negative radiological evaluation.
3. Discussion
Reports of medical rather than surgical management of
hydatidiform mole are scarce in the literature. Because of the
invasive nature of trophoblast and the malignant potential
of HM, optimal reduction of tumor mass is a key issue, and
surgical ablative treatment (suction curettage) to evacuate
the uterine content is therefore preferred above medical
methods. To our knowledge, this is the ﬁrst description
of primary treatment of an intrauterine hydatidiform mole
with methotrexate. We considered the use of methotrexate
analogous to its use in nonmolar ectopic pregnancies and
suggested that in general methotrexate could be considered
in patients with unevacuated or incompletely evacuated
molar pregnancy. Unfortunately, two cycles of methotrexate
treatmentinourcasefailedtoresultincompleteremissionof
the molar disease. Although there was no evidence of distant
metastases, preference was given to proceed with multiagent
chemotherapy with etoposide, methotrexate, actinomycin
(a)
(b)
Figure 1: CT-scan of the abdomen, performed for GTN staging
after two cycles of interval systemic methotrexate for hydatidiform
mole. White arrows indicate the presence of three ﬁbroids, resulting
in important distortion of the uterine cavity. At this stage, no
residual molar tissue was observed radiologically.

























tory response (A) to two cycles of methotrexate interval, followed
by a plateau-phase (B), indicating transition into a gestational
trophoblastic tumour. Six cycles of EMA/CO chemotherapy were
given subsequently (C).
D/cyclophosphamide, and vincristine (EMA/CO), over the
single-agent actinomycin D. We are aware that single-agent
with actinomycin D is indicated when the hCG value
reaches a plateau below 100IU/L, as happened in the case
presented here, but we argued that the absence of a complete
histological analysis of the mole, and the inherent potential
of having undetected an invasive component of the tumor,
justiﬁed the delivery of multiagent chemotherapy.Case Reports in Medicine 3
With this report, we aim to highlight a potential pitfall
that is encountered when women of advanced reproductive
age have a hydatidiform mole and present with distortion
of the uterine cavity by ﬁbroids. In our case, standard
surgical treatment was not possible and nonmetastatic GTN
developed following treatment with single-agent methotrex-
ate. Nevertheless, until further experience is available, we
recommend carefully monitored single-agent chemotherapy
with methotrexate in the rare circumstance where uterine
anomalies preclude standard surgical treatment.
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